AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT01504698 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Advice and exercise-based treatment plus joint manipulation
Description: The treatment can consist of advice, activation and exercise and/or manual soft-tissue treatment plus joint manipulation.The areas and frequency of manipulative treatment will be determined by the chiropractor and will consist of high-velocity, low-amplitude manipulation and/or mobilization to the spine and/or the extremities.
Study NCT01504698 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Advice and exercise-based treatment
Description: The treatment can consist of advice, activation and exercise and/or manual soft-tissue treatment. However, assisted stretching is not allowed as this will approach mobilization.
Study NCT02351024 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OXP005
Study NCT02351024 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Naprosyn®
Study NCT01163760 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: etafilcon A
Description: daily disposable contact lens
Study NCT01163760 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: ocufilcon D
Description: daily disposable contact lens
Study NCT03515317 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: theta/beta NF
Description: The goal of theta/beta NF is to increase the beta power(13-20 Hz) and simultaneously inhibit the theta power (4-8 Hz) relative to a baseline assessed at the beginning of a training session. The electrodes will be placed on Fz and Cz with a linked ear model(A1). The study will use both visual and auditory feedback. Each participant will sit in front of a computer screen on which predesigned games or animations related to the training criteria are played and instructions regarding the inhibitory and reward aspects of the training are taught. The threshold will be set according to 5-min baseline EEG measurements before each session. The thresholds are the mean amplitude of the beta and the theta in 5-min baseline EEG.
Study NCT01425580 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: liraglutide
Description: 1.8 mg s.c. (QD)
Study NCT01425580 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: liraglutide
Description: 1.8 mg s.c. (QD)
Study NCT01425580 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: glimepiride
Description: 4 mg p.o. (QD)
Study NCT01425580 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: glimepiride
Description: 4 mg p.o. (QD)
Study NCT01425580 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metformin
Description: 500 mg p.o. (BID)
Study NCT01425580 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin
Description: 500 mg p.o. (BID)
Study NCT01481194 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxorubicin
Description: 50 mg/m2 IV on day 1 of a 21-day cycle
Study NCT01481194 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bortezomib
Description: 1.3 mg/m2 IV push on days 2 and 9 of a 21-day cycle
Study NCT01481194 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenalidomide
Description: 15 mg orally on days 1-14 of a 21-day cycle
Study NCT01481194 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: 20 mg orally on days 2, 3, 9, and 10 of a 21-day cycle
Study NCT01481194 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: 750 mg/m2 IV on day 1 of a 21-day cycle
Study NCT05547009 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Blended-learning group
Description: The BL program included paced, asynchronous online learning modules and scheduled online activities with strategic face-to-face lectures. Resources: 1) Moodle platform: it was used as a virtual communication platform. 2) Online syllabus: an online specific syllabus about cardiac physiotherapy was developed. 3) Online glossary: an online glossary performed by the teacher was available for the students. 4) Online videos: several videos of international and national scientific societies were provided. 5) Websites: several links to websites of international and national scientific societies such as the European Society of Cardiology, the American Heart Association or the World Heart Federation were used. 6) Online activities: five four-question online activities were created. 7) Apps, using the app Ariadna to prevent from cardiovascular risk and look for defibrillators around; 8) Online tutorship, through an online communication platform (Blackboard Collaborate).
Study NCT05547009 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Face-to-face learning group
Description: The FLG included: 1) Face-to-face classes; 2) Hardcopy syllabus; 3) Hardcopy scien-tific societies information; 4) Face-to-face activities: four questions per each theme; 5) Hardcopy glossary; and 6) Face-to-face tutorships. In all cases, the content of the infor-mation provided was the same as the information provided to the BLG, although in a face-to-face design.
Study NCT04114617 — intervention group
Intervention type: OTHER
Intervention: Starch-thickened liquids
Description: Thickener added in amounts required to reach slightly thick, mildly thick, moderately thick and extremely thick consistencies, as defined by the International Dysphagia Diet Standardisation Initiative flow test.
Study NCT04114617 — intervention group
Intervention type: OTHER
Intervention: Xanthan-gum thickened liquids
Description: Thickener added in amounts required to reach slightly thick, mildly thick, moderately thick and extremely thick consistencies, as defined by the International Dysphagia Diet Standardisation Initiative flow test.
Study NCT04114617 — intervention group
Intervention type: COMBINATION_PRODUCT
Intervention: Barium concentration
Description: Commercially available barium products diluted to different concentrations (i.e., 20% w/v, 40% w/v) through the addition of water
Study NCT01127828 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Arla Yoghurt with no probiotic
Description: two servings of 200 ml of investigational products per day
Study NCT04258982 — intervention group
Intervention type: OTHER
Intervention: no intervention
Description: no intervention
Study NCT05210738 — intervention group
Intervention type: DEVICE
Intervention: Single incision sling
Description: Single incision sling is used to treat occult SUI
Study NCT05210738 — intervention group
Intervention type: DRUG
Intervention: Bulkamid bulking agent
Description: Urethral bulking by Bulkamid is used to treat occult SUI
Study NCT01223365 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hydrocodone ER
Description: Hydrocodone bitartrate extended-release tablets were administered at doses of 15, 30, 45, 60, and 90 mg orally every 12 hours. During the open-label titration period, doses were adjusted until a stable pain control was achieved. In general, the dose of hydrocodone extended release tablets could be adjusted for efficacy or tolerability, as necessary, at any time during the open-label treatment period; however, participants were required to visit the study center before increasing the dose of study drug.
Study NCT02629094 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Inspra /Eplerenone
Description: Eplerenone is provided as 25- or 50-mg tablets that are to be taken orally. Subjects will be dosed at 25 mg daily for 1 week, and then 50 mg daily for 23 weeks. The total duration of dosing for each subject is 24 weeks.
Study NCT02024932 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BVS857
Description: BVS857 lyophilisate in vial; the lyophilisate was reconstituted with sterile water for injection, diluted as appropriate, and administered either i.v. or s.c..
Study NCT02024932 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo lyophilisate in vial; the lyophilisate was reconstituted with sterile water for injection, diluted as appropriate, and administered either i.v. or s.c..
Study NCT03020641 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Low pressure pneumoperitoneum
Description: Low pressure pneumoperitoneum
Study NCT03020641 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: standard pneumoperitoneum pressure
Description: standard pneumoperitoneum pressure
Study NCT01397630 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxytocin
Description: Accelerated Oxytocin Titration
Study NCT01397630 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oxytocin
Description: Accelerated Oxytocin Titration
Study NCT03099538 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ixekizumab
Description: Subcutaneous injection
Study NCT01372579 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: eribulin mesylate
Description: Given IV
Study NCT01372579 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: carboplatin
Description: Given IV
Study NCT01372579 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: biopsy
Description: Correlative studies
Study NCT00724256 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ceftibuten
Description: ceftibuten 9mg/kg once a day for 7 days.
Study NCT00724256 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ceftibuten
Description: ceftibuten 9mg/kg once a day for 10 days.
Study NCT01835093 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tipepidine Hibenzate
Study NCT02533362 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ANF-Rho
Description: Pegylated version of recombinant human granulocyte-colony stimulating factor (G-CSF)
Study NCT02628834 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Fascial mobilization
Description: The patient will lie on prone position with knee extension and therapist put the patient's plantar surface to her femoral region. Achilles, tibialis posterior, perenous longus and brevis distal tendons, gastrocnemius proximal tendons, hamstring's distal tendons will be mobilized at first stage. The second stage of fascia mobilization included the deep fascial mobilization of posterior crural muscle trunks. After that, the skin also will be gently mobilized. During fascial mobilization, once the spastic muscles relaxation will appeared, the ankle will move to dorsiflexion gradually. FM will carry out for 15 minutes for each foot.
Study NCT02628834 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Stretching Exercise
Description: Patients will receive also stretching exercises consisted of 30 s stretching and 10 s resting periods and will carry out for 15 minutes for each foot at second day after the first evaluation.
Study NCT03301285 — intervention group
Intervention type: DRUG
Intervention: Zoledronic Acid
Description: Treatment of osteoporosis
Study NCT01056965 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: davunetide (AL-108, NAP)
Description: Subjects will be randomized 2:1 (drug:placebo). Subjects will receive twice daily treatment with davunetide 15 mg administered intranasally.
Study NCT01056965 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo nasal spray
Description: Subjects will be randomized 2:1 (drug:placebo). Subjects will receive twice daily treatment with placebo administered intranasally.
Study NCT01535859 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cabergoline
Description: Cabergoline in 0.5mg tablet. 1 tablet daily for 8 days.
Study NCT01535859 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 1 tablet daily for 8 days.
Study NCT01829308 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: The brief interventions are delivered by behavioral health counselors (Specialist)
Description: Behavioral Health Specialists perform the brief intervention. The screening and referral to treatment processes remain the same as with the Generalist condition.
Study NCT01829308 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: The brief interventions are delivered by the primary care provider (Generalist)
Description: Primary care providers perform the brief intervention. The screening and referral to treatment processes remain the same as with the Specialist condition.
Study NCT03206619 — intervention group
Intervention type: OTHER
Intervention: Social, Local and Mobile
Description: Patients in a smoking cessation program will use a mobile application to receive messages and rate them from their smartphones. The messages patient will receive belong to one of the following five topics: general motivation, diet tips, physical exercise tips, personal performance, and the benefits of being a non-smoker. For each one of these topics, there will be a pool of 150 different messages with tailored information for the patient. Topics and messages were approved by a smoking cessation psychologist and a pulmonologist. The selection of the time the messages have to be sent, and the message topic is selected by an health recommender system algorithm based on the patients' user profile (demographic information, message rating information, and app interaction information).
Study NCT01127828 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Probiotic yoghurt (Cultura)
Description: 200 ml per day
Study NCT03192358 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Videofluoroscopic Swallowing Examination
Description: During the videofluoroscopy, subjects will take up to 21 sips of liquid, ranging in thickness from thin (like water), to extremely-thick (like pudding or custard). The liquids will be mixed with E-Z-Paque barium sulfate, to allow it to be visible on the x-ray.
Study NCT03192358 — intervention group
Intervention type: OTHER
Intervention: Tongue Strength Measurement
Description: We will measure tongue strength using a tongue pressure measurement system called the Iowa Oral Performance Instrument (IOPI). A small disposable bulb filled with air will be placed in the mouth, just behind the front teeth. Participants will be asked to press their tongue upwards against the bulb as hard as they can, three (3) times at the front of the tongue and three (3) times at the back of the tongue (i.e., total of six (6) maximum isometric tongue presses). Participants will also be asked to swallow their saliva with the bulb placed in their mouth, three (3) times.~Tongue pressure measurement will be completed twice in the data collection session - once at the beginning, and once at the end (following the videofluoroscopy).
Study NCT01915303 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pasireotide with or without cabergoline
Description: The trial consisted of Pasireotide-untreated patients who started pasireotide 0.6mg twice a day for 8 weeks. If biochemical control was not achieved by the end of the 8 weeks, and the 0.6mg dose is well-tolerated, the dose was increased to 0.9mg twice a day for another 8 weeks. If biochemical control is not achieved, cabergoline was added and patients began combination treatment with cabergoline at the starting dose of 0.5mg once a day for 8 weeks. If biochemical control is still not achieved at the end of the third 8 week period, the dose of cabergoline was increased to 1.0mg once a day. Patients could also immediately start the combination treatment by adding cabergoline 0.5mg once a day at study entry to their current maximal tolerated dose of pasireotide. Patients continued with the combination treatment for 8 weeks. If biochemical control was not not achieved by the end of the 8 week period, the dose of cabergoline was increased to 1mg once a day.
Study NCT01716416 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pazopanib
Study NCT01716416 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cetuximab
Study NCT02925338 — intervention group
Intervention type: OTHER
Intervention: QOL questionaire
Description: Health assessment questionnaire disability index for rheumatoid polyarthritis questionnaire
Study NCT02078856 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: A3384
Study NCT02078856 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: A3384
Study NCT04096768 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine
Description: Comparing Dexmedetomidine + Ketamine versus Dexmedetomidine + Placebo for sedation in ICU patients
Study NCT04096768 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Dexmedetomidine
Description: Comparing Dexmedetomidine + Ketamine versus Dexmedetomidine + Placebo for sedation in ICU patients
Study NCT04096768 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketamine
Description: Comparing Dexmedetomidine + Ketamine versus Dexmedetomidine + Placebo for sedation in ICU patients
Study NCT00146848 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Atrial support pacing through cardiac resynchronization therapy. Device: RENEWAL family of CRT-D devices
Description: All subjects in this trial receive the same device. For the purpose of this trial, intervention is programming mode and lower rate limit to deliver atrial support pacing in the two treatment arms, while the control arm will receive programming where limited atrial support pacing is delivered. DDD-70 and DDDR-40 are the treatment arms programmed to receive atrial support pacing and will be compared to the DDD-40 arm.
Study NCT03113890 — intervention group
Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: Phlebotomy - Folate
Description: This will be a blood draw performed at Visit 1 for Folate (one 7mL tube)
Study NCT03113890 — intervention group
Intervention type: GENETIC
Group type: OTHER
Intervention: Phlebotomy - Folate
Description: This will be a blood draw performed at Visit 1 for Folate (one 7mL tube)
Study NCT03113890 — intervention group
Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: Cheek Swab
Description: Participants will undergo a cheek swab to then be analyzed using the Genecept Assay created by Genomind, Inc. This will occur once during Visit 1.
Study NCT03113890 — intervention group
Intervention type: GENETIC
Group type: OTHER
Intervention: Cheek Swab
Description: Participants will undergo a cheek swab to then be analyzed using the Genecept Assay created by Genomind, Inc. This will occur once during Visit 1.
Study NCT03113890 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Self-report surveys
Description: At visit 1 and at visit 3 and 4, participants will be asked to complete self report diagnostic surveys and surveys related to the objective aims of the study.
Study NCT03113890 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Self-report surveys
Description: At visit 1 and at visit 3 and 4, participants will be asked to complete self report diagnostic surveys and surveys related to the objective aims of the study.
Study NCT01952808 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Face-to-face family mentoring and education sessions
Description: A total of 13 home visits will be completed over a 6 month period. In addition to an introductory/orientation visit, 12 home visits will consist of family mentoring/educational sessions focused on physical activity and healthy nutrition.
Study NCT01952808 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Telephone follow-up
Description: During months 7-12, a total of up to 12 phone calls will be completed. Follow-up calls will consist of a progress report from families on physical activity and healthy diet progress/goals, along with brief content follow-up and re-enforcement points from the 12 intervention sessions.
Study NCT01245569 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Foster® 100/6 µg/unit dose
Description: Foster® (beclomethasone dipropionate 100 µg plus formoterol 6 µg/unit dose), 2 inhalations b.i.d. (daily dose of BDP extrafine 400 µg plus FF 24 µg).
Study NCT01245569 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Seretide Accuhaler® 500/50 µg/actuation
Description: Seretide® Accuhaler® (fluticasone 500 μg plus salmeterol 50 μg/actuation), 1 inhalation b.i.d. (daily dose of fluticasone 1000 μg plus salmeterol 100 μg).
Study NCT04090372 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: evaluation of pre-op planning using Traumacad
Description: The study will be compare pre-op planning with standard condition or with TraumaCad
Study NCT01105767 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Chlorhexidine gluconate
Description: Self applied chlorhexidine body wash (4% chlorhexidine gluconate, Hibiclens®, Mӧlnlycke Heath Care, Norcross, Georgia) once a week to wash/cover the body (except the face and genitalia).
Study NCT01105767 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Supplemental training, education and hygiene
Description: Supplemental SSTI education for trainees and drill sergeants included pocket cards and posters. Drill sergeants received briefings on SSTI and skin inspection/minor wound care. Trainees were instructed to take an additional 10-minute shower with soap and a wash cloth every week. They were also issued a first aid kit.
Study NCT01279941 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Behavioral: Team-based intervention
Description: The intervention involves a scripted peer-taught interactive curriculum, which is delivered as twelve, one-hour weekly sessions incorporated into a team's usual work time activities, with four follow-up booster sessions after twelve months.
Study NCT00401232 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Blood Collection
Description: Blood Collection
Study NCT02840617 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Indocyanine Green (ICG)
Study NCT03123406 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cinacalcet HCl
Description: Administer Cinacalcet HCL to all subjects from 1st to 32nd week. Subjects choose to buy and take Cinacalcet HCL in real-world period from 33rd to 52nd week.
Study NCT01411735 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Enalapril
Description: 2.5mg titrated up to 10mg twice daily
Study NCT01411735 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: 2.5mg titrated up to 10mg twice daily.